Professor C Simon Herrington

• Prof Charlie Gourley, Oncology, University of Edinburgh
• Prof Mark Arends, Pathology, University of Edinburgh

Selected Publications

Hollis RL, Meynert AM, Michie CO, Rye T, Churchman M, Croy I, McCluggage WG, Williams ARW, Dougherty B, Matakidou A, March R, Barrett JC, Roxburgh P, Semple CA, Kennedy R, Herrington CS, Gourley C, "Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification", Clin Cancer Res. 2022; 283546-3556. doi: 10.1158/1078-0432.CCR-22-0368. PMID: 35696721.

Hollis RL, Croy I, Churchman M, Bartos C, Rye T, Gourley C, Herrington CS, "Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high grade serous carcinoma", Br J Cancer. 2022; 127: 1034–1042. doi: 10.1038/s41416-022-01874-8

Sanderson PA, Esnal-Zufiaurre A, Arends MA, Herrington CS, Collins F, Williams ARW, Saunders PTK, "Improving the diagnosis of endometrial hyperplasia using computerized analysis and immunohistochemical biomarkers", Front Reprod Health. 2022; 4: 896170. doi: 10.3389/frph.2022.896170 . PMID: 36303676.

Gershenson DM, Miller A, Brady WE, Paul J, Carty K, Rodgers W, Millan D, Coleman RL, Moore KN, Banerjee S, Connolly K, Alvarez Secord A, O’Malley DM, Dorigo O, Gaillard S, Gabra H, Slomovitz B, Hanjani P, Farley J, Churchman M, Ewing A, Hollis RL, Herrington CS, Huang HQ, Wenxel L, Gourley C, "Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): a randomized, open-label phase 2/3 trial", Lancet. 2022; 399: 541-553. doi: 10.1016/S0140-6736(21)02175-9. PMID: 35123694.

Vergote I, Gonzalez-Martin A, Lorusso D, Gourley C, Raza Mirza M, Kurtz JE, Okamoto A, Moore K, Kridelka F, McNeish I, Reuss A, Votan B, du Bois A, Mahner S, Ray-Coquard I, Kohn EC, Berek JS, Tan DSP, Colombo N, Zang R, Concin N, O’Donnell D, Rauh-Hain A, Herrington CS, Marth C, Poveda A, Fujiwara K, Stuart GCE, Oza A, Bookman MA, on behalf of the participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research. "Gynecologic Cancer InterGroup consensus recommendations on clinical research in ovarian cancer". Lancet Oncol. 2022; 23: e374-384. doi: 10.1016/S1470-2045(22)00139-5. PMID: 35901833.

Bouvard V, Wentzensen N, Mackie A, Berkhof J, Brotherton J, Rossi PG, Kupets R, Smith R, Arrossi S, Bendahhou K, Canfell, K, Chirenje M, Chung MH, del Pinto M, de Sanjose S, Elfstrom M, Franco E, Hamashima C, Hamers F, Herrington CS, Murillo R, Sangrajrang S, Sankaranarayanan R, Saraiya M, Schiffman M, Zhao F, Arbyn M, Prendiville W, Indave BI, Mosquera Metcalfe I, Lauby-Secretan B, "The IARC perspective on cervical cancer screening". N Engl J Med. 2021; 385: 1908-1918. doi: 10.1056/NEJMsr2030640. PMID: 34758259.

Hollis R, Stillie LJ, Hopkins S, Bartos C, Churchman M, Rye T, Nussey F, Fegan S, Nirsimloo R, Inman G, Herrington CS, Gourley C, "Clinicopathological determinants of recurrence risk and survival in mucinous ovarian carcinoma". Cancers (Basel). 2021; 13: 5839. doi: 10.3390/cancers13225839. PMID: 34830992.

Heong V, Miwa M, Tan TZ, Ye J, Lim D, Herrington CS, Iida Y, Yano M, Yasuda M, Ngoi NYL, Okamoto A, Gourley C, Hasegawa K, Tan DS, Huang RY, "A multi-ethnic analysis of immune-related gene expression signatures in patients with ovarian clear cell carcinoma". J Pathol. 2021; 255: 285-295. doi: 10.1002/path.5769. PMID: 34322886.

Hollis R, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean M, Nussey F, Okamoto A, Semple CA, Gourley C, Herrington CS, "Integrated molecular characterization of endometrioid ovarian carcinoma identifies opportunities for stratification", npj Precis Oncol. 2021; 5: 47. doi: 10.1038/s41698-021-00187-y. PMID: 34079052.

Ewing A, Meynert A, Churchman M, Grimes G, Hollis R, Herrington CS, Rye T, Bartos C, Croy I, Ferguson M, Lennie M, McGoldrick T, McPhail N, Siddiqui N, Dowson S, Glasspool R, Mackean M, Nussey F, McDade B, McMahon L, Matakidou A, Dougherty B, March R, Barrett JC, McNeish I, Biankin A, Roxburgh P, Gourley C, Semple C, "Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma", Clin Cancer Res. 2021; 27: 3201-3214. doi: 10.1158/1078-0432.CCR-20-4068. PMID: 33741650.

Hollis R, Thomson JP, Stanley B, Churchman M, Meynert AM, Rye T, Bartos C, Iida Y, Croy I, Mackean M, Nussey F, Okamoto A, Semple CA, Gourley C, Herrington CS, "Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome", Nat Commun. 2020; 11: 4995.  doi: 10.1038/s41467-020-18819-5. PMID: 33020491.

Irodi A, Rye T, Herbert K, Churchman M, Bartos C, Mackean M, Nussey F, Herrington CS, Gourley C, Hollis RL, "Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data", BJOG. 2020; 127: 1409-1420. doi: 10.1111/1471-0528.16264. PMID: 32285600.

Hollis RL, Stanley B, Iida Y, Thomson J, Churchman M, Rye T, Mackean M, Nussey F, Gourley C, Herrington CS, "Hormone receptor expression patterns define clinically meaningful subgroups of ovarian endometrioid carcinoma", Gynecol Oncol. 2019; 155: 318-323. doi: 10.1016/j.ygyno.2019.09.001. PMID: 31495455.

Hollis RL, Carmichael J, Meynert AM, Churchman M, Hallas-Potts A, Rye T, Mackean M, Nussey F, Semple CA, Herrington CS, Gourley C, "Clinical and molecular characterisation of ovarian carcinoma displaying isolated lymph node relapse", Am J Obstet Gynecol. 2019; 221: 245.e1-245.e15. doi: 10.1016/j.ajog.2019.04.035. PMID: 31055034. 

Hallas-Potts A, Dawson JC, Herrington CS, "Ovarian cancer cell lines derived from non-serous carcinomas migrate and invade more aggressively than those derived from high-grade serous carcinomas", Sci Rep. 2019; 9: 5515. doi: 10.1038/s41598-019-41941-4. PMID: 30940866.